Track topics on Twitter Track topics that are important to you
Global companion diagnostics market projected to grow at CAGR of 20.1%
The global companion diagnostics market is projected to reach USD 6.51 billion by 2022 from USD 2.61 billion in 2017, at a CAGR of 20.1%. The growth of this market is majorly driven by the factors such as improvements in regulatory guidelines, growing need for targeted therapies, rising cancer incidence across the globe, and increasing collaborations and partnerships for companion diagnostics test development. However, uncertain reimbursement scenarios in different countries such as the U.S., the U.K., Japan, and Australia are expected to limit market growth.
The assay kits reagents segment is expected to grow at the fastest CAGR'
On the basis of product and service, the companion diagnostics market is segmented into assay kits reagents, and software services. The assay kits reagents segment accounted for the largest share in 2016 and is expected to register the highest CAGR during the forecast period. The large share can be attributed to its wide range of applications in platforms such as PCR, NGS, IHC, and ISH.
The oncology segment to dominate the global companion diagnostics market with largest share and fastest CAGR
Based on indication, the companion diagnostics market is further categorized into oncology, infectious diseases, neurology, and other indications including cardiovascular, inflammatory, and inherited diseases. In 2016, the oncology segment accounted for the largest share and is also the fastest growing segment of the market; this is primarily attributed to the growing incidence of cancer that enhanced the focus on cancer research and also broadened the role of companion diagnostics in this field.
The pharmaceutical and biopharmaceutical companies segment is expected to grow at the fastest CAGR
On the basis of end user, the pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the market in 2016. This enduser segment is also expected to register the highest CAGR during the forecast period. The large share and growth of this market can be attributed to increasing and significant application of companion diagnostics in the drug development process.
AsiaPacific to witness the fastest growth during the forecast period 20172022
North America held the largest share of the global companion diagnostics market in 2016, while AsiaPacific is expected to witness the highest growth during 2017 to 2022. Growing need for tailored therapeutics by the elderly population, increasing number of hospitals and diagnostic laboratories, and growing prevalence of lifethreatening diseases are driving the growth of the companion diagnostics market in the AsiaPacific region.
Break of primary participants was as mentioned below:
By Company Type Tier 145%, Tier 234%, and Tier 321%
By Designation Clevel14%, Director Level10%, and Others76%
By Region North America40%, Europe32%, AsiaPacific20%, and RoW8%
Some of the major market players in the companion diagnostics market are F. HoffmannLa Roche AG Switzerland, Agilent Technologies, Inc. U.S., and QIAGEN N.V. Netherlands dominated the global companion diagnostics market. Some of the other players competing in this market are Thermo Fisher Scientific Inc. U.S., Abbott Laboratories, Inc. U.S., Myriad Genetics, Inc. U.S., Danaher Corporation U.S., Almac Group U.S., and Sysmex Corporation Japan.
The report analyzes the companion diagnostics market and aims at estimating market size and future growth potential of this market based on various segments such as product and service, type of medical device, application, and region. The report also includes an indepth regulatory analysis for various regions across the globe and competitive analysis of the key players in this market along with their company profiles, product and service offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help garner a greater share. Firms purchasing the report could use one or any combination of the belowmentioned five strategies.
This report provides insights on the following pointers:
Market Penetration: Comprehensive information on product and service portfolios offered by the top players in the global companion diagnostics market. The report analyzes the global companion diagnostics market by product and service, technology, indication, end user, and region
Product/Service Enhancement/Innovation: Detailed insights on upcoming trends and new product/service launches in the global companion diagnostics market
Market Development: Comprehensive information on the lucrative emerging markets by product and service, type of medical device, application, and region
Market Diversification: Exhaustive information about new product or product enhancements, growing geographies, recent developments, and investments in the global companion diagnostics market
Competitive Assessment: Indepth assessment of market shares, growth strategies, products, services, and capabilities of leading players in the global market.
Original Article: Companion Diagnostics Market by Technology PCR, IHC, NGS, ISH, Indication Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases, End User Pharmaceutical Biopharmaceutical Companies, Reference Lab Global Forecast to 2022 [RNEXT ARTICLE
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...
Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.